The Patent Finder

Neuracle Science Co., Ltd.

22 patents currently held · Updated Nov 16, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 2 name spellings.

0
Ending by 2030
Feb 2033
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 2 fees due Feb 20 to 28, 2027 · next Feb 20
  • 1 fee due Mar 5, 2027
    The maintenance fee for Use of anti-family with sequence similarity 19, member A5 antibodies for the treatment of glaucoma (US 11,746,149) comes due Mar 5, 2027. Unpaid by Sep 7, 2027, it lapses early.
  • 1 fee due Oct 30, 2027
    The maintenance fee for Anti-Family with Sequence Similarity 19, Member A5 Antibodies and Method of Use Thereof (US 11,970,532) comes due Oct 30, 2027. Unpaid by May 1, 2028, it lapses early.
  • 1 fee due Nov 5, 2027
    The maintenance fee for Pharmaceutical Use of FAM19A5 Involved in Regulating Gliogenesis (US 10,640,557) comes due Nov 5, 2027. Unpaid by May 5, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 9,579,398Pharmaceutical Use of FAM19A5 Involved in Regulating Gliogenesis
In force
 · High confidence
In forceHigh confidence
US 10,640,557Pharmaceutical Use of FAM19A5 Involved in Regulating Gliogenesis
In force
 · Medium confidence
In forceMedium confidence
US 11,739,141Pharmaceutical use of FAM19A5 involved in regulating gliogenesis
In force
 · From the USPTO record
In forceFrom the USPTO record
US 12,435,130Pharmaceutical Use of FAM19A5 Involved in Regulating Gliogenesis
In force
 · Medium confidence
In forceMedium confidence
US 10,385,098Agonist of spexin-based galanin type 2 receptor and use thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,248,023Agonist of spexin-based galanin type 2 receptor and use thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,332,521Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 12,202,889Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,155,613Use of anti-FAM19A5 antibodies for treating fibrosis
In force
 · From the USPTO record
In forceFrom the USPTO record
US 12,492,246ANTI-FAM19A5 Antibodies and Uses Thereof
In force
 · High confidence
In forceHigh confidence
10 of 22 patents shown.
Pro members see all 22.
Pro members: see all 22 patents

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

14 pending · 3 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited